Evotec Collaborated with Almirall to Discover and Develop Novel Therapies for the Treatment of Skin Diseases
Shots:
- Evotec receives $241.23M up front, research fees & is eligible to receive success-based milestones along with royalties on net sales. Additionally, both companies will contribute drug targets in the research process
- The collaboration will use Evotec's AI/ML-driven EVOiR&D platform and Almirall's expertise in Medical Dermatology to discover and develop novel therapies for the treatment of severe skin diseases including immune-mediated inflammatory conditions i.e., AD and non-melanoma skin cancer
- Evotec will lead the drug discovery & pre-clinical development while Almirall will be responsible for the clinical development and marketing of the product
Ref: accesswire| Image: Evotec
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
